The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Association of emergent neuroendocrine prostate cancer detected by liquid biopsies with survival and treatment resistance.
 
Amy K Taylor
No Relationships to Disclose
 
Jamie M Sperger
No Relationships to Disclose
 
Marina Nasrin Sharifi
No Relationships to Disclose
 
Yue Shi
No Relationships to Disclose
 
Charlotte Stahlfeld
No Relationships to Disclose
 
Jennifer L. Schehr
No Relationships to Disclose
 
Hamid Emamekhoo
Consulting or Advisory Role - Cardinal Health; Exelixis; Seagen; Seagen
 
Christos Kyriakopoulos
Stock and Other Ownership Interests - Biogen; Epic Systems (I)
Consulting or Advisory Role - AVEO; EMD Serono; Exelixis; Janssen Oncology; Janssen Oncology; Sanofi
Research Funding - AstraZeneca; ESSA; Gilead Sciences; Pionyr; Sanofi
 
Andrew J. Armstrong
Consulting or Advisory Role - Astellas Scientific and Medical Affairs Inc; AstraZeneca; Bayer; Bristol-Myers Squibb; Epic Sciences; Exelixis; FORMA Therapeutics; GoodRx; IDEAYA Biosciences; Janssen; Merck; Myovant Sciences; Novartis; Pfizer
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Constellation Pharmaceuticals (Inst); Dendreon (Inst); FORMA Therapeutics (Inst); Gilead Sciences (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Circulating tumor cell novel capture technology (Inst)
Travel, Accommodations, Expenses - Astellas Scientific and Medical Affairs Inc
 
Xiao X. Wei
Honoraria - OncLive
Consulting or Advisory Role - Novartis
Research Funding - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Corvus Pharmaceuticals
 
Mary-Ellen Taplin
Honoraria - Abbvie; Arcus Biosciences; Arvinas; AstraZeneca; Blue Earth Diagnostics; Clovis Oncology; Constellation Pharmaceuticals; Epizyme; Hengrui Therapeutics; Janssen-Ortho; Pfizer; Propella Therapeutics; Research to Practice; Roivant; Targeted Oncology; UpToDate
Consulting or Advisory Role - Arcus Ventures (I); AstraZeneca; Bayer; Best Doctors, Inc; Clovis Oncology; Janssen-Ortho; Myovant Sciences; Pfizer; Research to Practice; UpToDate
Research Funding - Janssen-Ortho (Inst)
Travel, Accommodations, Expenses - Advanced Prostate Cancer Society
 
Rana R. McKay
Consulting or Advisory Role - Astellas Medivation; AstraZeneca; AVEO; Bayer; Bristol-Myers Squibb; Calithera Biosciences; Caris Life Sciences; Dendreon; Exelixis; Janssen; Merck; Myovant Sciences; Novartis; Pfizer; Sanofi; Sorrento Therapeutics; Tempus; Vividion Therapeutics
Research Funding - Bayer (Inst); Pfizer (Inst); Tempus (Inst)
 
Shuang Zhao
Employment - Exact Sciences (I)
Stock and Other Ownership Interests - Exact Sciences (I)
Patents, Royalties, Other Intellectual Property - Patent applications pending licensed to Veracyte
 
Joshua Michael Lang
Stock and Other Ownership Interests - Salus Discovery
Consulting or Advisory Role - 4D Pharma; 4D Pharma; Arvinas; AstraZeneca; Gilead Sciences; Immunomedics; Janssen; Pfizer/Astellas; Pfizer/Myovant; Sanofi; Sanofi
Research Funding - Agensys (Inst); Arvinas (Inst); Bristol-Myers Squibb (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Janssen (Inst); Medivation (Inst)
Patents, Royalties, Other Intellectual Property - I am listed on the patent on a technology for rare cell capture and analysis. This technology has been licensed by Salus Discovery, LLC though no commercial products are available.